Patient Portal

Nancy Lee Bartlett, MD

Professor, Medicine
Division of Oncology
Koman Chair in Medical Oncology

Specialty Areas

Medical Oncology
Oncology
Hematologic Malignancies
Lymphoma

Board Certifications

Internal Medicine
Oncology

Hospital Affiliations

Barnes-Jewish Hospital

Areas of Clinical Interest

Non-Hodgkin's and Hodgkin's lymphoma, chronic lymphocytic leukemia, hematologic malignancies

  • Location(s)
  • Education
  • Publication & Research

Location(s)

Location(s)

Center for Advanced Medicine
Siteman Cancer Center

4921 Parkview Place
St. Louis, MO 63110

Suite: B
Floor: 7
Office Phone: 314-747-1171
Fax: 314-747-5123

Education

Education

Fellowship: Medical Oncology, Stanford University, California 1993
Chief Residency: Medicine, University of California, San Francisco, California 1990
Residency: Medicine, University of California, San Francisco, California 1989
Medical Degree: Washington University School of Medicine, St. Louis, Missouri 1986
M.S.: Chemical Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts 1979
B.A.: Chemical Engineering, Stanford University, California 1978

Publication & Research

Publication & Research

Final 5-year findings from the phase 3 HELIOS study of ibrutinib plus bendamustine and rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.
Fraser GAM, Chanan-Khan A, Demirkan F, Santucci Silva R, Grosicki S, Janssens A, Mayer J, Bartlett NL, Dilhuydy MS, Loscertales J, Avigdor A, Rule S, Samoilova O, Pavlovsky MA, Goy A, Mato A, Hallek M, Salman M, Tamegnon M, Sun S, Connor A, Nottage K, Schuier N, Balasubramanian S, Howes A, Cramer P
Leuk Lymphoma. 2020 Aug 6; 1-10. doi: 10.1080/10428194.2020.1795159.

PMID:
    32762271
    [PubMed - as supplied by publisher]
Related citations


A phase 1b study of AFM13 in combination with pembrolizumab in patients with relapsed or refractory Hodgkin lymphoma.
Bartlett NL, Herrera AF, Domingo-Domenech E, Mehta A, Forero-Torres A, Garcia-Sanz R, Armand P, Devata S, Rodriguez Izquierdo A, Lossos IS, Reeder C, Sher T, Chen R, Schwarz S, Alland L, Strassz A, Prier K, Choe-Juliak C, Ansell SM
Blood. 2020 Jul 30; pii: blood.2019004701. doi: 10.1182/blood.2019004701.

PMID:
    32730586
    [PubMed - as supplied by publisher]
Related citations


Hodgkin lymphoma.
Connors JM, Cozen W, Steidl C, Carbone A, Hoppe RT, Flechtner HH, Bartlett NL
Nat Rev Dis Primers. 2020 Jul 23; 6(1)61. doi: 10.1038/s41572-020-0189-6.

PMID:
    32703953
    [PubMed - in process]
Related citations


Positron Emission Tomography-Directed Therapy for Patients With Limited-Stage Diffuse Large B-Cell Lymphoma: Results of Intergroup National Clinical Trials Network Study S1001.
Persky DO, Li H, Stephens DM, Park SI, Bartlett NL, Swinnen LJ, Barr PM, Winegarden JD 3rd, Constine LS, Fitzgerald TJ, Leonard JP, Kahl BS, LeBlanc ML, Song JY, Fisher RI, Rimsza LM, Smith SM, Miller TP, Friedberg JW
J Clin Oncol. 2020 Jul 13; JCO2000999. doi: 10.1200/JCO.20.00999.

PMID:
    32658627
    [PubMed - as supplied by publisher]
Related citations


CAR-modified memory-like NK cells exhibit potent responses to NK-resistant lymphomas.
Gang M, Marin ND, Wong P, Neal CC, Marsala L, Foster M, Schappe T, Meng W, Tran J, Schaettler M, Davila ML, Gao F, Cashen AF, Bartlett NL, Mehta-Shah N, Kahl B, Kim M, Cooper ML, DiPersio JF, Berrien-Elliott MM, Fehniger TA
Blood. 2020 Jul 2; pii: blood.2020006619. doi: 10.1182/blood.2020006619.

PMID:
    32614951
    [PubMed - as supplied by publisher]
Related citations


Polatuzumab vedotin for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma.
Malecek MK, Watkins MP, Bartlett NL
Expert Opin Biol Ther. 2020 Jun 15; 1-9. doi: 10.1080/14712598.2020.1777979.

PMID:
    32500753
    [PubMed - as supplied by publisher]
Related citations


Longitudinal Toxicity over Time (ToxT) analysis to evaluate tolerability: a case study of lenalidomide in the CALGB 50401 (Alliance) trial.
Thanarajasingam G, Leonard JP, Witzig TE, Habermann TM, Blum KA, Bartlett NL, Flowers CR, Pitcher BN, Jung SH, Atherton PJ, Tan A, Novotny PJ, Dueck AC
Lancet Haematol. 2020 Jun; 7(6)e490-e497. doi: 10.1016/S2352-3026(20)30067-3.

PMID:
    32470440
    [PubMed - indexed for MEDLINE]
Related citations


Multicenter Study of Risk-Adapted Therapy With Dose-Adjusted EPOCH-R in Adults With Untreated Burkitt Lymphoma.
Roschewski M, Dunleavy K, Abramson JS, Powell BL, Link BK, Patel P, Bierman PJ, Jagadeesh D, Mitsuyasu RT, Peace D, Watson PR, Hanna WT, Melani C, Lucas AN, Steinberg SM, Pittaluga S, Jaffe ES, Friedberg JW, Kahl BS, Little RF, Bartlett NL, Fanale MA, Noy A, Wilson WH
J Clin Oncol. 2020 Aug 1; 38(22)2519-2529. doi: 10.1200/JCO.20.00303.

PMID:
    32453640
    [PubMed - in process]
Related citations


Potential impact of consolidation radiation therapy for advanced Hodgkin lymphoma: a secondary analysis of SWOG S0816.
Ha CS, LeBlanc M, Schöder H, Pinnix CC, Bartlett NL, Evens AM, Hsi ED, Rimsza L, Knopp MV, Zhang J, Leonard JP, Kahl BS, Li H, Smith S, Constine LS, Friedberg JW
Leuk Lymphoma. 2020 May 26; 1-6. doi: 10.1080/10428194.2020.1768388.

PMID:
    32452714
    [PubMed - as supplied by publisher]
Related citations


Diffuse Telangiectatic Rash Associated With Novel Antibody Drug Conjugate Therapies.
Sorensen EP, Thrush J, Bartlett NL, Rosman IS, Anadkat MJ, Jones HA
JAMA Dermatol. 2020 Apr 8; doi: 10.1001/jamadermatol.2020.0208.

PMID:
    32267477
    [PubMed - as supplied by publisher]
Related citations


Prognostic value of interim FDG-PET in diffuse large cell lymphoma: results from the CALGB 50303 Clinical Trial.
Schöder H, Polley MC, Knopp MV, Hall N, Kostakoglu L, Zhang J, Higley HR, Kelloff G, Liu H, Zelenetz AD, Cheson BD, Wagner-Johnston N, Kahl BS, Friedberg JW, Hsi ED, Leonard JP, Schwartz LH, Wilson WH, Bartlett NL
Blood. 2020 Jun 18; 135(25)2224-2234. doi: 10.1182/blood.2019003277.

PMID:
    32232481
    [PubMed - in process]
Related citations


The justification of vincristine dose capping: tradition, tradition…tradition!
Bartlett NL
Leuk Lymphoma. 2020 May; 61(5)1007-1009. doi: 10.1080/10428194.2020.1742907.

PMID:
    32212887
    [PubMed - in process]
Related citations


Outcomes of older patients in ZUMA-1, a pivotal study of axicabtagene ciloleucel in refractory large B-cell lymphoma.
Neelapu SS, Jacobson CA, Oluwole OO, Munoz J, Deol A, Miklos DB, Bartlett NL, Braunschweig I, Jiang Y, Kim JJ, Zheng L, Rossi JM, Locke FL
Blood. 2020 Jun 4; 135(23)2106-2109. doi: 10.1182/blood.2019004162.

PMID:
    32181801
    [PubMed - in process]
Related citations


Bortezomib consolidation or maintenance following immunochemotherapy and autologous stem cell transplantation for mantle cell lymphoma: CALGB/Alliance 50403.
Kaplan LD, Maurer MJ, Stock W, Bartlett NL, Fulton N, Pettinger A, Byrd JC, Blum KA, LaCasce AS, Hsi ED, Liu YT, Scott DW, Hurd D, Ruppert AS, Hernandez-Ilizaliturri F, Leonard JP, Cheson BD
Am J Hematol. 2020 Jun; 95(6)583-593. doi: 10.1002/ajh.25783.

PMID:
    32170769
    [PubMed - indexed for MEDLINE]
Related citations


First-in-Human Study of Utomilumab, a 4-1BB/CD137 Agonist, in Combination with Rituximab in Patients with Follicular and Other CD20+ Non-Hodgkin Lymphomas.
Gopal AK, Levy R, Houot R, Patel SP, Popplewell L, Jacobson C, Mu XJ, Deng S, Ching KA, Chen Y, Davis CB, Huang B, Fly KD, Thall A, Woolfson A, Bartlett NL
Clin Cancer Res. 2020 Jun 1; 26(11)2524-2534. doi: 10.1158/1078-0432.CCR-19-2973.

PMID:
    32144134
    [PubMed - in process]
Related citations


Rituximab/bendamustine and rituximab/cytarabine induction therapy for transplant-eligible mantle cell lymphoma.
Merryman RW, Edwin N, Redd R, Bsat J, Chase M, LaCasce A, Freedman A, Jacobson C, Fisher D, Ng S, Crombie J, Kim A, Odejide O, Davids MS, Brown JR, Jacene H, Cashen A, Bartlett NL, Mehta-Shah N, Ghobadi A, Kahl B, Joyce R, Armand P, Jacobsen E
Blood Adv. 2020 Mar 10; 4(5)858-867. doi: 10.1182/bloodadvances.2019001355.

PMID:
    32126141
    [PubMed - in process]
Related citations


Brentuximab vedotin with chemotherapy for stage III/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study.
Straus DJ, Długosz-Danecka M, Alekseev S, Illés Á, Picardi M, Lech-Maranda E, Feldman T, Smolewski P, Savage KJ, Bartlett NL, Walewski J, Ramchandren R, Zinzani PL, Hutchings M, Connors JM, Radford J, Munoz J, Kim WS, Advani R, Ansell SM, Younes A, Miao H, Liu R, Fenton K, Forero-Torres A, Gallamini A
Blood. 2020 Mar 5; 135(10)735-742. doi: 10.1182/blood.2019003127.

PMID:
    31945149
    [PubMed - in process]
Related citations


Treatment of Nodular Lymphocyte Hodgkin Lymphoma: The Goldilocks Principle.
Bartlett NL
J Clin Oncol. 2020 Mar 1; 38(7)662-668. doi: 10.1200/JCO.19.02816.

PMID:
    31922929
    [PubMed - in process]
Related citations


Implication of Rituximab Infusion Reactions on Clinical Outcomes in Patients With Diffuse Large B-cell Lymphoma: A Single Institution Experience.
Patel DA, Johanns TM, Trinkaus K, Bartlett NL, Wagner-Johnston N, Cashen AF
Clin Lymphoma Myeloma Leuk. 2019 Dec; 19(12)806-811. doi: 10.1016/j.clml.2019.09.604.

PMID:
    31648954
    [PubMed - in process]
Related citations


Reply to T.M. Weis et al.
Bartlett NL, Wilson WH, Leonard JP
J Clin Oncol. 2019 Nov 1; 37(31)2953. doi: 10.1200/JCO.19.01617.

PMID:
    31532721
    [PubMed - indexed for MEDLINE]
Related citations